Done deal — Buyout takes Durham pharma off the Nasdaq

Just more than a month after it was announced, Dova Pharmaceuticals’ buyout by a Swedish biotech is complete.

The Durham drugmaker disclosed the news Sept. 30, that it was being acquired by Swedish Orphan Biovitrum (OM: SOBI).

According to a securities filing, SOBI paid about $868 million in cash.

Here's who's in line to profit from Dova's buyout

On Tuesday – the day the deal closed – Dova terminated and repaid a loan and security agreement among Dova, Silicon Valley Bank and others.


Previous AAC finalizing details to join new exchange following NYSE delisting
Next Mylan and Upjohn announce name of combined company

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *